Author

Zhi-Ping Wu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD) remain lethal malignancies with limited therapeutic options, highlighting an urgent need for more effective treatments. Integrin αvβ6 (ITGB6) is a receptor preferentially expressed in specific types of tumors, such as PDAC and LUAD, and represents a...

Ling-Chao Shi, L. Qin, Shu-Xin Sun et al. · Molecular Cancer Therapeutic... · 0 citations

Open access Sep 2026

Gut microbiota characteristics of gastric cancer patients across distinct pathological stages and their associations with tumor and paratumor mucosal microbiota

Gastric cancer (GC) is closely associated with microbial dysbiosis; however, the spatial–temporal characteristics of the gut, paracancerous, and intratumoral microbiomes, as well as their interrelationships during tumor progression, remain insufficiently defined. This study aimed to characterize these microbiomes in...

Guo-Qing Qi, Zhi-Ping Wu, Juan-Juan Chen et al. · Frontiers in Cellular and In... · 0 citations

Aug 2026

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.

The prognosis of non-small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is dismal. The regulators of LM progression remain elusive, thus impeding effective clinical intervention. Here, we performed in vivo genome-wide CRISPR-based screens and found that fused in sarcoma (FUS) ablation promoted LM in bot...

Shou-Heng Lin, Kai Yin, M. Zheng et al. · Science Translational Medici... · 0 citations